广生堂：公司目前暂未安排该试验中期揭盲分析计划

Core Viewpoint - The company is actively advancing its Phase III clinical trial for GST-HG141, a key project in its innovative drug development pipeline, but has not scheduled a mid-term data unblinding analysis to ensure data integrity [1] Group 1 - The Phase III clinical trial for GST-HG141 is a 48-week randomized double-blind study [1] - The company is committed to efficiently progressing the trial and will disclose significant advancements in innovative drug development in a timely manner [1] - The company appreciates the support and interest from investors regarding the trial [1]